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Aberrant Wnt/b-catenin signaling following loss of
the tumor suppressor adenomatous polyposis coli
(APC) is thought to initiate colon adenoma formation.
Using zebrafish and human cells, we show that
homozygous loss of APC causes failed intestinal
cell differentiation but that this occurs in the absence
of nuclear b-catenin and increased intestinal cell
proliferation. Therefore, loss of APC is insufficient
for causing b-catenin nuclear localization. APC
mutation-induced intestinal differentiation defects
instead depend on the transcriptional corepressor
C-terminal binding protein-1 (CtBP1), whereas prolif-
eration defects and nuclear accumulation of b-cate-
nin require the additional activation of KRAS. These
findings suggest that, following APC loss, CtBP1
contributes to adenoma initiation as a first step,
whereas KRAS activation and b-catenin nuclear
localization promote adenoma progression to carci-
nomas as a second step. Consistent with this model,
human FAP adenomas showed robust upregulation
of CtBP1 in the absence of detectable nuclear
b-catenin, whereas nuclear b-catenin was detected
in carcinomas.
INTRODUCTION
Mutations in the adenomatous polyposis coli (APC) tumor
suppressor gene initiate the process of colon carcinogenesis
(Kinzler and Vogelstein, 1996). Current studies indicate that
APC functions in normal colon to negatively regulate the Wnt
signaling by targeting b-catenin for degradation by the proteo-
some (Bienz and Clevers, 2000; Clevers, 2006). Wild-type APC
plays a central role in a destruction complex that includes
Axin, GSK-3b, and casein kinase 1 (CK1). This complex directsa series of phosphorylation events on b-catenin that target it
for ubiquitination and subsequent proteolysis (Polakis, 2002).
In cells harboring mutated APC, b-catenin accumulates and,
following its translocation into the nucleus, is thought to coacti-
vate TCF-LEF (Morin, 1999; Polakis, 1999). b-catenin/TCF-LEF-
dependent transcriptional activation of cell-cycle regulatory
genes, like c-myc (He et al., 1998) and cyclin D1 (Tetsu and
McCormick, 1999), serves as the mechanistic basis for explain-
ing the APC mutation-dependent initiation of colon adenomas.
The current model of APC function predicts an immediate acti-
vation of Wnt signaling upon homozygous loss of APC. This view
places aberrant Wnt signaling, along with APC mutation, as the
initiating event for intestinal adenoma formation. Manipulation
of Apc in murine models offers considerable support for the
immediate dysregulation of Wnt signaling following APC loss
(Hinoi et al., 2007; Kongkanuntn et al., 1999; Sansom et al.,
2004). In these models, dysregulation and nuclear accumulation
of b-catenin appear coincident with the development of early
adenomas. Stabilizing mutations in b-catenin, rather than muta-
tions in APC, are found in 7% of sporadic human colon carci-
nomas and provide additional genetic evidence directly linking
APC and b-catenin (Iwao et al., 1998; Morin et al., 1997; Sparks
et al., 1998). Indeed, transgenic mice carrying stabilized, mutant
b-catenin develop numerous intestinal adenomas (Romagnolo
et al., 1999). Taken together, these studies offer dysregulation
of b-catenin as a compelling model that describes the molecular
events that accompany APC loss and colon tumor initiation.
Despite accumulating evidence supporting the current model,
several studies have failed to confirm the nuclear accumulation
of b-catenin upon APC mutation in early human colon
adenomas. Anderson et al. examined the subcellular localization
of b-catenin in grossly uninvolved and adenoma tissues taken
from FAP patients and were unable to detect nuclear b-catenin
in greater than 90% of the adenomas examined. However,
nuclear b-catenin was readily detected in sporadic adenocarci-
nomas (Anderson et al., 2002). Similarly, Blaker et al. examined
early adenomas with mild dysplasia and late adenomas with
significant dysplasia. Although they observed elevated levels of
b-catenin in the early adenomas, this b-catenin was confinedCell 137, 623–634, May 15, 2009 ª2009 Elsevier Inc. 623
to the cytoplasm. Again, they did detect nuclear b-catenin in the
late adenomas (Blaker et al., 2003). Based on these observa-
tions, both groups concluded that homozygous loss of APC
alone is insufficient for nuclear accumulation of b-catenin. In
agreement with these findings, recent analysis of microadeno-
mas and late adenomas taken from a rat model (PIRC) carrying
a targeted Apc truncation revealed detectable levels of nuclear
b-catenin only in the late adenomas (Amos-Landgraf et al.,
2007). Taken together, these findings suggest that Wnt activa-
tion, as assessed by nuclear accumulation of b-catenin, may
require events in addition to loss of APC. Further, these findings
raise the possibility that initiation of adenoma formation following
APC loss occurs independently of b-catenin.
KRAS mutations are evident in as many as 40% of colon
cancers (Bos et al., 1987; Forrester et al., 1987) and can arise
early in adenoma development. Consistent with the multihit
hypothesis for colon tumor development (Fearon and Vogelstein,
1990), reports in mice indicate that the combination of APC loss
and KRAS mutation causes an increase in adenoma size,
number, and invasiveness (Janssen et al., 2006; Sansom et al.,
2006) and promotes the expansion of cells bearing putative
stem cell markers within the tumor epithelium (Haigis et al.,
2008). Although these studies have demonstrated a critical rela-
tionship between APC and KRAS, the models employed limit
analysis of the immediate consequences of APC loss on intes-
tinal cells. As such, the precise sequence of events and under-
lying mechanisms contributing to adenoma formation remain
unclear. Herein, we employ comparative studies in zebrafish
and human cell lines to show that APC mutation-induced intes-
tinal cell-fating defects result from dysregulation of C-terminal
binding protein-1 (CtBP-1) rather than activation of b-catenin.
Further, although the activation of b-catenin controls cell prolifer-
ation, this proliferative response requires KRAS, RAF, and RAC1
in addition to APC loss.
RESULTS
KRAS Promotes Intestinal Cell Proliferation
and Activation of b-Catenin following Loss of APC
Homozygous apc mutant zebrafish (apcmcr) embryos display
a variety of profound developmental defects and facilitate inter-
rogation of the immediate morphologic and mechanistic conse-
quences of apc loss (Hurlstone et al., 2003; Nadauld et al., 2004).
In examining sagital- and cross-sections of the entire intestine
of apcmcr zebrafish embryos, we noted an unexpected 34%
decrease in the total number of intestinal epithelial cells (Figures
1A and Figure S1 and Table S1 available online), suggesting an
absence of Wnt signaling in these cells. Consistent with this
possibility, immunofluorescence staining revealed that, whereas
b-catenin was robustly upregulated in intestinal cells, its localiza-
tion was confined to the cytoplasm (Figure 1A). To test whether
oncogenic KRAS might constitute an additional trigger needed
to stimulate intestinal cell proliferation and accumulation of
nuclear b-catenin following loss of apc, we injected apcmcr
zebrafish with mRNA-encoding oncogenic V5-KRASG12D (here-
after referred to as KRAS). Western analysis confirmed expres-
sion of KRAS protein in injected embryos and indicated activa-
tion of the KRAS-signaling pathway by the presence of624 Cell 137, 623–634, May 15, 2009 ª2009 Elsevier Inc.increased phospho-ERK (Figure 1B). Injection of KRAS alone
failed to induce intestinal cell proliferation or nuclear accumula-
tion of b-catenin (Figure 1A and Table S1). In contrast, injection of
KRAS into apcmcr embryos (hereafter referred to as APC-KRAS)
caused a robust proliferative response, as indicated by a 4-fold
increase in intestinal cell number relative to apcmcr and robust
expression of pcna (Figure 1A and Table S1). Consistent with
a requirement for KRAS activity in the nuclear accumulation of
b-catenin and a requirement for b-catenin in directing intestinal
cell proliferation, nuclear b-catenin was evident only in the
proliferative APC-KRAS intestinal cells (Figure 1A).
As predicted from the above findings, zebrafish harboring
a TOPdGFP reporter construct lacked detectable expression
of intestinal GFP upon knockdown of apc (Figures 1C and S1)
or injection of KRAS only (Figure 1C). However, APCmoKRAS-
TOPdGFP embryos displayed robust expression of GFP
(Figure 1C) within the intestines, thereby confirming the activa-
tion of b-catenin coincident with its nuclear localization and the
proliferative state of the intestinal cells. In contrast to the intes-
tines, control-injected TOPdGFP embryos showed strong
expression of GFP within the hindbrain region and the lens as
seen previously (Nadauld et al., 2006a). Consistent with a role
for apc and kras in these tissues, knockdown of apc alone or
injection of KRAS mRNA each increased GFP expression in
comparison to control embryos. This induction was further
enhanced by coincident knockdown of apc along with injection
of KRAS (Figure 1C).
KRAS and RAF1 Mediate Nuclear Localization
of b-Catenin
Next, we determined which KRAS effectors mediated targeting
of b-catenin to the nucleus. Injection of either constitutively
active RAF1 (RAF1) or MEK1 (MEK1) into wild-type embryos
failed to induce nuclear accumulation of b-catenin or intestinal
cell proliferation. Again, increased phospho-erk confirmed the
presence of active RAF1 and MEK1 in these embryos
(Figure S2). As seen with KRAS, injection of apcmcr embryos
with RAF1 caused increased intestinal cell proliferation and
accumulation of nuclear b-catenin (Figure 2A and Table S1). In
contrast, injection of MEK1 into apcmcr embryos failed to
enhance intestinal cell proliferation or accumulation of nuclear
b-catenin (Figure 2A and Table S1), thereby suggesting a require-
ment for RAF1, but not MEK1, in KRAS regulation of b-catenin.
A mek1-independent role of kras and raf1 was also evident in
that APC-KRAS and APC-RAF1 embryos shared distinct
morphologic phenotypes not present in APC-MEK1 embryos
(Figure S2). For example, we noted the occurrence of a cyclops
phenotype in 40% of the APC-KRAS or APC-RAF1 embryos
that was absent in the APC-MEK1 embryos (Figure 5A and
data not shown).
To confirm the above findings in human cell lines, we em-
ployed the SW-480 colon cancer cell line, as it harbors mutated
APC and oncogenic KRAS and shows robust staining for nuclear
b-catenin (Figure 2B). Specific targeting of endogenous KRAS or
RAF1 using multiple, distinct siRNAs caused a redistribution of
nuclear b-catenin to the cytoplasm (Figures 2B, S2, and S3).
This was paralleled by the downregulation of the known b-cate-
nin target gene Axin2 (Figure 2C). Inhibition of MEK1 by
transfection of a dominant-negative construct or by using the
pharmacologic inhibitor U0126 failed to alter b-catenin subcel-
lular localization (Figures 2B and S3) despite decreasing phos-
pho-ERK levels (Figure S3). In confirming specificity of the
knockdown studies, cotransfection of cells with siKRASG12V
and constitutively active KRAS or RAF1 (Figures 2D and S3)
restored localization of b-catenin to the nucleus. Again, CA-
MEK1 was ineffective (Figures 2D and S3).
Next, we sought to manipulate the accumulation and subcel-
lular distribution of b-catenin in zebrafish and human 293 cells
Figure 1. KRAS Promotes Intestinal Cell
Proliferation and Nuclear Localization of
b-Catenin following Loss of APC
(A) apcmcr zebrafish embryos were injected at the
one-cell stage with KRAS mRNA. The 72 hpf
embryos were fixed, sectioned, and stained for
hematoxylin and eosin (H&E) (row 1, sagital
section; row 2, cross section), DNA (magenta,
middle and bottom), and either PCNA (middle,
green) or b-catenin (bottom, green). Overlapping
expression is shown in white.
(B) Protein lysates from 72 hpf embryos were sub-
jected to western blot analysis for either V5-tag
(top-left) and total RAS (bottom-left) or phospho-
Erk (top-right) and vinculin (bottom-right).
(C) Zebrafish harboring an integrated b-catenin
TOPGFP reporter were injected with KRAS
mRNA, APC morpholino, or both. The 72 hpf
embryos were subjected to whole-mount in situ
hybridization for GFP. Boxes indicate the intestine
(top), and arrows indicate the hindbrain (bottom).
All images were captured using the same expo-
sure and represent at least three independent
experiments. Scale bar, 10 mm.
containing wild-type APC. Recent
studies have implicated PGE2 in stabi-
lizing b-catenin following loss of APC
(Castellone et al., 2005; Eisinger et al.,
2007; Shao et al., 2005). In agreement
with these findings, treatment of wild-
type zebrafish with PGE2 mirrored loss
of apc and increased cytoplasmic levels
of b-catenin without affecting cell prolif-
eration (Figure 3A). Injection of KRAS
mRNA coincident with PGE2 treatment
increased pcna expression and nuclear
localization of b-catenin (Figure 3A)
within the intestinal epithelial cells.
In assessing this observation in human
cells, treatment of 293 cells with PGE2
alone or transfection with KRAS showed
little change in the subcellular localization
of b-catenin (Figure 3B). In contrast,
treatment with PGE2 along with transfec-
tion with KRAS showed redistribution of
b-catenin to the nucleus (Figures 3B
and S3), thereby supporting a require-
ment for KRAS activity in stimulating the
translocation of PGE2-stabilized b-catenin into the nucleus of
human cells. In support of the results above, expression of
RAF1, but not MEK1 (Figure 3B), along with PGE2 exposure
also promoted robust redistribution of b-catenin into the
nucleus. This redistribution was confirmed by western blotting
of nuclear fractions (Figure S3). Exposure of cells to PGE2 and
the nuclear export inhibitor leptomycin B failed to stimulate
accumulation of nuclear b-catenin (Figure 3C) and eliminated
nuclear retention as an underlying mechanism. As a control,
we found robust nuclear retention of Mondo A in response toCell 137, 623–634, May 15, 2009 ª2009 Elsevier Inc. 625
leptomycin B (data not shown). Interestingly, EGF effectively
recapitulated the action of KRAS (Figure 3D) and caused nuclear
accumulation of b-catenin within 15 min of exposure (Figure S3).
Figure 2. KRAS and RAF1 Are Necessary for Nuclear Localization of
b-Catenin and Intestinal Cell Proliferation following Loss of APC
(A) apcmcr zebrafish embryos injected with constitutively active RAF1 or MEK1.
The 72 hpf embryos were stained for hematoxylin and eosin (H&E) staining
(top), DNA (magenta, middle and bottom), and either PCNA (middle, green)
or b-catenin (bottom, green).
(B) SW-480 cells transfected with control, KRASG12V, RAF1-directed siRNA, or
DN-MEK1 constructs were stained for DNA (magenta) and b-catenin (green).
(C) RNA was harvested and subjected to rt-PCR for Axin2. Error bars, SEM.
(D) SW-480 cells transfected with KRASG12V-specific siRNA were cotrans-
fected with constitutively active KRAS, RAF1, or MEK1 and stained for DNA
(magenta) and b-catenin (green).
Overlapping expression is shown in white. All images were captured using the
sameexposureand represent three independentexperiments.Scalebar, 10mm.626 Cell 137, 623–634, May 15, 2009 ª2009 Elsevier Inc.Consistent with a role for KRAS and RAF1, siRNA targeting of
either block the actions of EGF. Further, EGF enhanced cell
growth following treatment of cells with PGE2 (Figure 3E). This
demonstrates that activation of KRAS and RAF1, either through
oncogenic mutation or growth factor stimulation, signals to
regulate b-catenin nuclear localization.
KRAS/RAF1 Regulation of b-Catenin Requires
the Activity of RAC1
Previous studies have implicated RAC1 in controlling the nuclear
localization of b-catenin in cells responding to Wnt ligand
(Wu et al., 2008). As phosphorylation of serine 191 and 605 on
b-catenin depended upon RAC1, we transfected SW-480 cells
with b-catenin constructs carrying mutations in either of these
sites and noted that b-catenin remained in the cytoplasm
(Figure 4A), despite the presence of mutant APC. In contrast,
constructs bearing mutations in known PKA-dependent phos-
phorylation sites (Taurin et al., 2006) (552 and 675) effectively
accumulated in the nucleus (Figure 4B). Consistent with these
findings, inhibition of RAC1 prevented the nuclear accumulation
of b-catenin (Figures 4C and S4) and was accompanied by
decreased cell growth (Figure 4D). Inhibition of the closely
related Cdc42 failed to affect the localization of b-catenin
(Figures 4C and S4). As predicted from the above findings, inhi-
bition of either KRAS or RAF1 reduced the levels of GTP-bound
RAC1. In contrast, dominant-negative inhibition of MEK1 failed
to deactivate RAC1 (Figure 4E). We also noted reduced levels
of phospho-cJun (a downstream readout of RAC1 activation)
upon inhibition of RAC1, but not upon inhibition of Cdc42
(Figure 4F). As expected, inhibition of KRAS or RAF1, but not
MEK1, also resulted in decreased phospho-cJun staining
(Figure 4F). Finally, expression of constitutively active RAC1
(CA-RAC1) along with stimulation by PGE2 substituted fully for
KRAS or RAF1 in promoting the nuclear accumulation of b-cate-
nin in 293 cells (Figure 4G).
KRAS Enhances the Activity of Oncogenic b-Catenin
Because APC has been implicated in regulating a number of
cellular functions (Bienz and Hamada, 2004; Hanson and Miller,
2005; Nadauld et al., 2004, 2005, 2006a, 2006b; Takacs et al.,
2008), it was important to test whether the observed KRAS
synergy was mediated through b-catenin. Therefore, we asked
whether KRAS enhanced the activity of mutated, stabilized
b-catenin injected into wild-type embryos. Upon injection of
low levels of stabilized b-catenin alone, we noticed that 5%
of the embryos displayed the cyclops phenotype present in the
APC-KRAS embryos (Figure 5A). Therefore, we decided to
exploit this phenotype to determine whether the effects of
KRAS were synergistic with b-catenin. Consistent with a genetic
relationship between KRAS and b-catenin, injection of wild-type
zebrafish with stabilized, oncogenic b-catenin and KRAS gave
similar results to the APC-KRAS embryos (Figure 5B) in that
nearly 75% of the embryos displayed the cyclops phenotype
(Figure 5B). Injection of KRAS showed no effect. (Note: Examina-
tion of the intestines of these embryos showed an apparent
increase in cell number. However, the gut tube also duplicated.
Therefore, we were unable to distinguish gut duplication from
increased cell number due to proliferation.) As a measure of
in vivo activity, the 191 and 605 mutants failed to synergize with
KRAS in promoting a cyclops phenotype in zebrafish embryos
(data not shown).
APC Mutation-Induced Intestinal Cell Differentiation
Defects Occur Independently of b-Catenin
To evaluate the role of b-catenin in intestinal cell proliferation and
differentiation defects following apc loss, we used the COX-2
Figure 3. KRAS and RAF1 Direct Stabilized b-Cat-
enin to the Nucleus
(A) WT and KRAS-injected zebrafish embryos treated with
PGE2 were stained for DNA (magenta), PCNA (green), and
b-catenin (green).
(B) Human 293 cells were transfected with constitutively
active KRAS, RAF1, or MEK1 and either DMSO (top) or
PGE2 (bottom). Cells were stained for DNA (magenta)
and b-catenin (green).
(C) 293 cells treated with DMSO, PGE2 or PGE2, and lep-
tomycin B were stained for DNA (magenta) and b-catenin
(green).
(D) 293 cells were transfected with control or KRAS- or
RAF1-directed siRNA and treated with EGF and PGE2 or
vehicle and then stained for DNA (magenta) and b-catenin
(green).
(E) 293 cells were subjected to an MTT assay (*p < 0.05
versus DMSO; error bars, SEM).
Overlapping expression is shown in white. All images were
captured using the same exposure and represent three
independent experiments. Scale bar, 10 mm.
inhibitor (NS-398) (Eisinger et al., 2007) to
decrease the level of b-catenin in APC-KRAS
zebrafish (Figure 5C). We found that this treat-
ment effectively abrogated the KRAS-depen-
dent increase in intestinal cell number and
pcna staining (Figure 5D and Table S1). This
change was accompanied by reduced levels
of nuclear b-catenin and expression of intestinal
TOPdGFP (Figure 5D). Similar to findings seen
in zebrafish, inhibition of COX-2 resulted in
decreased nuclear accumulation of b-catenin
(Figure 5E) and cell growth (Figure 5F). Notably,
inhibition of COX-2 failed to restore morpholog-
ical features typical of differentiated intestinal
epithelial cells (Figure 5D).
As a number of studies have demonstrated
a relationship between APC and the transcrip-
tional corepressor C-terminal binding protein-1
(CtBP1) (Fang et al., 2006; Hamada and Bienz,
2004; Nadauld et al., 2006b; Sierra et al.,
2006), we determined the contribution of ctbp
and b-catenin to the observed lack of differenti-
ation present in homozygous apcmcr embryos.
As seenpreviously (Nadauld et al., 2006b), injec-
tion of awild-type fragment of APC (APC955–2075)
into apcmcr zebrafish embryos caused coinci-
dent downregulation of b-catenin and ctbp1
(Figure 6A) and restored the normal expression
pattern of the intestinal differentiation marker
i-fabp (Figure 6B). In contrast, injection of an APC construct
containing site-directed mutants in the three SAMP motifs
(APC955–2075-AALP) needed for AXIN binding (Spink et al., 2000)
failed to regulate either b-catenin or ctbp1 (Figure 6A) and failed
to restore i-fabp expression (Figure 6B) and indicated a role for
the AXIN-binding motifs in regulating both b-catenin and CtBP.
Because APC955–2075 regulated both b-catenin and CtBP, we
examined the b-catenin and ctbp1 dependence of severalCell 137, 623–634, May 15, 2009 ª2009 Elsevier Inc. 627
Figure 4. KRAS/RAF1 Regulation of b-Catenin Requires the Activity of RAC1
(A and B) SW-480 cells transfected with vehicle or myc-tagged ([A], S191A or S605A) or flag-tagged ([B], S552A or S675A) b-catenin mutants were stained for
DNA (magenta) and a-myc ([A], green) or a-flag ([B], green).
(C) SW-480 cells were transfected with RAC1-directed siRNA, DN-RAC1, and DN-Cdc42 or treated with the RAC1-specific inhibitor NSC23766 and stained for
DNA (magenta) and b-catenin (green).
(D) SW-480 cells were subjected to an MTT assay (*p < 0.05 versus DMSO; error bars, SEM).
(E) SW-480 cells were transfected with vehicle, KRASG12V-targeted siRNA, RAF1 siRNA, or DN-MEK1 and subjected to a RAC1 activity assay. The western blot
was probed for RAC1 (top). Control lysates were probed for total RAC1 (bottom).
(F) SW-480 cells treated as above were stained for phospho-cJun.
(G) Human 293 cells transfected with constitutively active RAC1 and treated with PGE2 or DMSO were stained for DNA (magenta) and b-catenin (green).
All images were captured using the same exposure and are representative of at least three independent experiments. Scale bar, 10 mm.intestinal cell fate (hoxa13a and evx1) and terminal differentiation
markers (i-fabp and NaPi) that show aberrant expression
patterns within the intestine of apcmcr zebrafish embryos. For
example, hoxa13a and evx1 showed expansion of their expres-
sion domain from confinement within the proctodeum to expres-
sion throughout the intestinal tube (Figure 6C). On the other
hand, apcmcr zebrafish embryos lacked expression of i-fabp
and NaPi (Figure 6C) present in wild-type embryos. To further
delineate the roles of ctbp1 and b-catenin in controlling the aber-
rant expression of these markers, we treated the embryos with
the COX-2 inhibitor NS-398 or injected apcmcr embryos with
two separate morpholinos targeting ctbp1 (Figures 6C and S6).
As shown in Figure 6C and consistent with our above findings,628 Cell 137, 623–634, May 15, 2009 ª2009 Elsevier Inc.NS-398-mediated downregulation of b-catenin failed to restore
the normal expression of ifabp, NaPi, hoxa13a, or evx1, indi-
cating the b-catenin independence of these defects. In contrast,
knockdown of ctbp1 rescued each of themarkers. Further, inclu-
sion of NS-398 failed to affect rescue following knockdown of
ctbp1 and indicated that ctbp1 suppresses intestinal differentia-
tion following loss of apc independently of b-catenin.
JNK Activation Is Coincident with Nuclear b-Catenin
in Human Carcinoma Samples
To extend our findings to human tissues, we examined 20
matched sets of grossly uninvolved and adenoma tissues from
FAP patients along with 20 sporadic carcinoma samples for
Figure 5. KRAS-Mediated Intestinal Cell Proliferation following Loss of APC Requires b-Catenin
(A) Zebrafish embryos were injected with b-cateninS45A mRNA (left) along with KRAS mRNA (middle). Also shown is a representative image of the APC-KRAS
embryo (right). At 72 hpf, the embryos were fixed and photographed.
(B) The percent cyclops was analyzed (*p < 0.01 WT versus b-catenin-KRAS, **p < 0.01 WT versus APC-KRAS).
(C) Protein was harvested from apcmcr embryos treated with DMSO or NS-398 and subjected to western blot analysis for b-catenin (top) or vinculin (bottom).
(D)Wild-type uninjected or apcmcr embryos injected with KRASmRNA treatedwith VEH (top) or NS-398 (bottom) were stained by H&E (WT, left; APC-KRAS, right)
and for DNA (magenta), PCNA (green), and b-catenin (green). TOPGFP-APCmo-KRAS embryos were stained for GFP expression (purple). Boxes indicate the
intestine.
(E) SW-480 cells treated with DMSO or NS-398 were stained for DNA (magenta) and b-catenin (green). Protein lysates were subjected to western blot analysis for
b-catenin (top) and vinculin (bottom).
(F) Cells were subjected to MTT analysis (*p < 0.05 versus DMSO; error bars, SEM).
Overlapping expression is shown in white. All images were captured using the same exposure and represent at least three independent experiments. Scale
bar, 10 mm.expression and localization of CtBP1, b-catenin, and phospho-
cJun (as an indicator of JNK activity). This analysis revealed up-
regulation of CtBP1 in the nucleus of both human adenoma and
carcinoma tissues (Figure 7A). In these same samples and
similar to our finding in apcmcr zebrafish intestines above, there
was an apparent increase in the level of b-catenin staining in
the adenomatous tissues compared to the grossly uninvolvedtissue (Figure 7B). However, as reported previously, this staining
was confined to cytoplasm (Anderson et al., 2002; Blaker et al.,
2003). Adjacent tissue sections showed no evidence of cJun
phosphorylation (Figure 7C). In contrast, nuclear b-catenin was
detected in carcinomas (Figure 7B) and was paralleled by
increased levels of phospho-cJun (Figure 7C). (Note: Figure 6
shows two representative images. The remaining 18 samplesCell 137, 623–634, May 15, 2009 ª2009 Elsevier Inc. 629
are shown in Figures S7, S8, and S9. These 18 samples showed
similar qualitative staining patterns as those utilized as represen-
tative images. Demographic information for each sample is
provided in Table S2.)
DISCUSSION
Considerable evidence implicates dysregulated Wnt/b-catenin
signaling as the initiating event underlying colon adenoma
formation following loss of APC (Bienz and Clevers, 2000;
Clevers, 2006). Despite this evidence, studies examining human
FAP adenomas raise the possibility that APC loss alone is insuf-
ficient to promote aberrant Wnt/b-catenin signaling (Anderson
et al., 2002; Blaker et al., 2003). Further, although the genetic
relationship between APC and KRAS mutation in promoting
Figure 6. apc Control of Cellular Fate and
Differentiation Are Mediated by ctbp1 and
Are b-Catenin Independent
(A) Protein from 48 hpf apcmcr zebrafish embryos
injected with either 6 3 His-APC955–2075 or 6 3
His-APC955–2075-AALP were subjected to western
blot analysis for b-catenin (top), ctbp1 (second),
6 3 His (third), or vinculin (bottom).
(B) Embryos injected as above were fixed at 72 hpf
and subjected to in situ hybridization for i-fabp.
(C) apcmcr embryos were treated with DMSO or
NS-398 or injected with ctbp1-directed morpho-
lino in the presence or absence of NS-398. At
72 hpf, the embryos were fixed and subjected to
in situ hybridization for i-fabp, NaPi, hoxa13a, or
evx1.
All images are representative of at least three
independent experiments.
colon tumor development is well estab-
lished (Fearon and Vogelstein, 1990;
Janssen et al., 2006; Sansom et al.,
2006), the roles for APC loss and KRAS
mutation are largely viewed as indepen-
dent in the process of tumorigenesis,
and KRAS may only exacerbate Wnt
signaling following APC mutation.
Through juxtaposition of zebrafish with
human cell lines, we present evidence
that APC and KRAS play distinct but
essential roles in controlling the stability
and nuclear accumulation of b-catenin.
Our findings support a model wherein
APC loss alone stabilizes the levels of
cytoplasmic b-catenin. This stabilization,
however, is insufficient for stimulating
nuclear accumulation of b-catenin and
intestinal cell proliferation. Rather, the
nuclear accumulation of b-catenin and
attendant proliferation require the activi-
ties of KRAS and RAF1. Signaling bet-
ween KRAS/RAF1 and b-catenin occurs
independently of MEK1 and instead relies
on a role of RAC1 and JNK2 in promoting nuclear localization of
b-catenin. These findings suggest that b-catenin-dependent
intestinal cell proliferation may contribute to adenoma progres-
sion, rather than initiation following loss of APC.
Our findings offer a mechanistic explanation for data that have
failed to confirm the presence of nuclear b-catenin in early
adenomas taken from both human and rat tissues harboring
mutatedAPC. For example, Anderson et al. reported that greater
than 90% of adenomas taken from FAP patients lacked detect-
able nuclear b-catenin (Anderson et al., 2002). Further, Blaker
et al. examined adenomas from FAP patients and concluded
that, although all of the adenomas acquired homozygous loss
of APC, none of the specimens displayed detectable nuclear
accumulation of b-catenin (Blaker et al., 2003). In each of
these studies, nuclear b-catenin was readily observed in more630 Cell 137, 623–634, May 15, 2009 ª2009 Elsevier Inc.
advanced lesions. In addition, in a recently developed Apcmuta-
tion-dependent rat model of colorectal cancer, the PIRC model,
nuclear b-catenin was not evident in microadenomas (Amos-
Landgraf et al., 2007) but was detectable in later-stage
adenomas. As with these studies, we were unable to detect
nuclear b-catenin in the intestines of homozygous apcmcr zebra-
fish embryos and in human FAP adenomas. However, we found
a mechanistic requirement for KRAS in promoting the nuclear
localization of b-catenin in the intestinal cells of zebrafish
carrying apc mutation and in human colon cancer cell lines.
Figure 7. JNK1 Activation Is Coincident
with Nuclear Accumulation of b-Catenin in
Human Tumor Samples
FFPE human-matched grossly uninvolved and
adenoma samples obtained from FAP patients
and unmatched sporadic carcinomas were
stained to indicate DNA (magenta) and (A) CtBP
(green), (B) b-catenin* (green), or (C) phospho-
cJun (green) as an indicator of JNK activity.
Overall, 20 patients matched grossly uninvolved,
and adenoma or unmatched carcinoma tissue
samples were stained. Shown are two representa-
tive samples. All images were captured using the
same exposure, and overlapping expression is
shown in white.
*Note: A section from each of the b-catenin-
stained adenomas was enlarged to the right.
Each antibodywas evaluated using serial sections.
Scale bar, 5 mm.
Furthermore, we observed that the pres-
ence of nuclear b-catenin in sporadic
human carcinomas was paralleled by
evidence of RAC1 activation. A need for
KRAS activity in regulating nuclear accu-
mulation of b-catenin provides a mecha-
nistic basis for the differential staining of
nuclear b-catenin in early versus late
adenomas and carcinomas (Amos-Land-
graf et al., 2007; Anderson et al., 2002;
Blaker et al., 2003) and suggests a depen-
dent, common regulatory point for APC
loss and KRAS activity in the develop-
ment of colon cancer.
The findings examining b-catenin
subcellular localization in human tissues
and zebrafish differ from a large body of
data regarding the consequence of Apc
mutation in mice. These studies have
demonstrated the occurrence of nuclear
b-catenin in very early lesions following
loss of Apc (Hinoi et al., 2007; Kongka-
nuntn et al., 1999; Sansom et al., 2004,
2006). Furthermore, a recent study ruled
out the presence of mutated Kras in early
adenoma development (Hinoi et al.,
2007). As an important distinction, these
studies have not formally tested a role
for Kras or Raf1 in adenoma formation or in directing the nuclear
localization of b-catenin following loss of APC. Interestingly,
Sansom et al. did observe activation of Tiam1, the major Rac1-
GEF, at the earliest time point showing evident nuclear b-catenin
in mice (Sansom et al., 2004). Our data implicating KRAS, RAF1,
and RAC1 in the control of b-catenin subcellular distribution sug-
gested a previously unappreciated molecular link between
growth factor signaling and APC loss. Indeed, we found that
treatment of human cells with EGF substituted for mutational
activation of KRAS or RAF in controlling the nuclearCell 137, 623–634, May 15, 2009 ª2009 Elsevier Inc. 631
accumulation of b-catenin. Previous work has implicated EGF
signaling in neoplastic tissue development in the murine intes-
tine. First, Roberts et al. demonstrated an essential role for
EGF in the establishment and maintenance of adenomas in the
Apcmin mouse (Roberts et al., 2002). In addition, Moran et al. re-
ported that adenomas fromApcminmice display increased EGFR
activity (Moran et al., 2004). Taken together, the current data
suggest that EGF signaling could actively support the nuclear
accumulation of b-catenin in the absence of Kras mutation.
Apcmcr zebrafish contain a truncating mutation in apc at posi-
tion 1318, which is within the mutation cluster region of APC as
defined based on the occurrence of mutations underlying human
colon cancer (Hurlstone et al., 2003). Studies examining adult
apcmcr heterozygous zebrafish revealed infrequent tumor forma-
tion that was enhanced by administration of the nonspecific
chemical carcinogen DMBA (Haramis et al., 2006). Because
these studies did not examine the mutational status of apc or
kras or a requirement for raf1 or rac1 in tumor formation, it is
unclear how the mutagen enhanced tumor formation. Similarly,
the APC1638N mutation in mice results in few lesions within
the intestines at 3.5 months. Notably, when crossed with the
villin-driven KRASG12V mouse, Apc1638N mice develop
numerous lesionswithin the intestine. In agreement with our find-
ings, lesions taken from the APC1638N-KRAS mice showed
enhanced nuclear b-catenin (Janssen et al., 2006). The require-
ment for Kras in the development of adenomas in the
Apc1638N mouse appears in contrast to murine models that
have utilized more severe truncation or complete loss of Apc.
In comparison, these mice develop more numerous lesions
following manipulation of Apc alone. However, several of these
models also appear to show synergy between Apc and Kras.
For example, Sansom et al. demonstrated that activation of
Kras along with Apcmutation caused a more aggressive pheno-
type with more invasive lesions (Sansom et al., 2006). Addition-
ally, Haigis et al. demonstrated that adenocarcinomas frommice
carrying an activated Kras and a truncated Apc allele had an
expanded stem cell population in intestinal adenomas (Haigis
et al., 2008).
A number of examples now invoke posttranslational modifica-
tion of b-catenin as critical to its subcellular localization and
activity. Our data implicating RAC1 in controlling b-catenin
nuclear localization downstream of KRAS are in direct agree-
ment with recent studies by Wu et al. These investigators
demonstrated that Wnt-ligand-mediated b-catenin nuclear
accumulation depended on Rac1 activity and that Rac1 control
of b-catenin was essential for normal development of the hin-
dlimb in mouse embryos (Wu et al., 2008). In agreement with
these studies, we have shown a requirement for RAC1 in regu-
lating nuclear localization of b-catenin in the presence of
mutated APC and oncogenic KRAS. This finding elucidates
a signaling pathway downstream of KRAS that relies on RAF,
but not MEK, and may provide a mechanistic basis for several
recent observations. First, Haigis et al. found that tumor growth
in APC-K-ras mice was refractory to MEK inhibition but that
colon cancer cell line growth depends on RAF1. In addition,
data from a recent phase II clinical trial showed that MEK inhibi-
tion did not significantly affect colorectal cancer progression as
measured by tumor growth (Rinehart et al., 2004). It is interesting632 Cell 137, 623–634, May 15, 2009 ª2009 Elsevier Inc.to note that human colon tumors bear mutations in both KRAS
and RAF. However, to date, there are no reports of oncogenic
mutation in MEK1 in colorectal cancer (Gripp et al., 2007). In
contrast, two groups have reported expression of the constitu-
tively active RAC1 splice variant RAC1b in colon tumors (Esufali
et al., 2007; Singh et al., 2004).
Undetectable nuclear b-catenin in early human adenomas and
apcmcr zebrafish intestines is paradoxical in that these tissues
show profound morphologic and molecular abnormalities.
Indeed, defects in cell fating and differentiation have been appre-
ciated in zebrafish (Haramis et al., 2006) andmurine (Haigis et al.,
2008) models of Apc truncation and attributed to dysregulation
of b-catenin. Our findings indicate that defects in intestinal cell
fating and differentiation following loss of Apc occur indepen-
dently of b-catenin. Although it is possible that the levels of
nuclear b-catenin are below the limits of detection in these
tissues, this level of b-catenin does not appear sufficient for
promoting intestinal cell proliferation, nor is it essential for sup-
pressing intestinal differentiation in apcmcr zebrafish. Rather,
ctbp1 accumulation following apc loss underlies these defects.
Consistent with this model, CtBP1 is highly expressed in human
adenomas lacking evident nuclear b-catenin. APC control of
both CtBP1 and b-catenin could shed light on the distinct clinical
phenotypes of colon tumors arising from mutations in APC
versus those harboring mutations in b-catenin (Samowitz et al.,
1999). Taken together, the above findings indicate that other
functions of Apc, such as regulation of Ctbp, play important roles
in early adenoma development and provide an important new
perspective on the ordering of molecular events that may
underlie colon tumor initiation and progression.
EXPERIMENTAL PROCEDURES
Zebrafish Embryo Culture and Manipulation
Wild-type, apcmcr, and TOPGFP Danio rerio (zebrafish) were maintained on
a 14 hr/10 hr light/dark cycle. Additionally, morpholino oligonucleotides target-
ing apc and ctbp1, whole-mount in situ hybridization, and hematoxylin and
eosin staining were carried out as described previously (Nadauld et al.,
2004). Inhibition of COX-2 and treatment with PGE2 was accomplished as
described previously (Eisinger et al., 2007). mRNA for KRASG12D or b-cate-
ninS45A was synthesized using mMESSAGE mMACHINE (Ambion) according
to the manufacturer’s instructions. mRNA was injected into embryos at the
one-cell stage. pCEP4-DNA plasmids containing constitutively active RAF1
and MEK1 were gifts from C. Jette (Harvard University) and were injected
into apcmcr embryos at the one-cell stage.
Human and Zebrafish Tissue Immunofluorescence
Immunofluorescence was carried out on formalin-fixed human tissue sections
or on 72 hpf zebrafish embryos. Embryos were fixed in 4% paraformaldehyde
in PBS and then dehydrated to 70% ethanol. The 7 mm thick, paraffin-
embedded sections were deparaffinized in xylenes and rehydrated in graded
alcohols and then permeabilized for 15 min in 0.1% Triton X-100 in PBS.
Antigen retrieval was performed by boiling for 15 min in 10 mM sodium citrate
buffer (pH 6.0) followed by cooling to room temperature. Sections were then
incubated in blocking buffer (2% goat serum and 1% bovine serum albumin
in 1 3 PBS) for 4 hr at room temperature and incubated in wash buffer
(0.2% goat serum, 0.1% bovine serum albumin, and 5 mM glycine in 1 3
PBS) for 2 hr at room temperature. Primary antibody (ms-a-PCNA, AbCam;
rb-a-b-catenin, Sigma; ms-a-b-catenin, BD Transduction Laboratories; and
rb-a-p-cJun, Calbiochem; diluted 1:250 in PBS) was applied overnight at
4C. Sections were rinsed twice in PBS and incubated for 2 hr at room temper-
ature in secondary antibody (gt-a-ms Alexa 488 and gt-a-rb Alexa 568,
Molecular Probes; dilution 1:250) and the nuclear stain TO-PRO-3 (Molecular
Probes; dilution 1:1000). Sections were rinsed in water, and coverslips were
applied using ProLong Gold antifade reagent (Molecular Probes).
Human Cell Immunofluorescence
Cells were grown on coverslips and grown to 70% confluency before treat-
ments. Following treatment, cells were washed twice with cold PBS and fixed
for 15 min at room temperature in 3.7% paraformaldehyde in PBS. Cells were
then washed three times in cold PBS and permeabilized for 30 min in PBS-T.
Cells were then incubated overnight at 4C in primary antibody (ms-a-b-cate-
nin, BD Transduction Laboratories; rb-a-p-cJun, Calbiochem; diluted 1:250 in
PBS-T). The following day, cells were washed three times in cold PBS and
incubated for 1 hr at room temperature in secondary antibody (gt-a-ms Alexa
488 or gt-a-rb Alexa 568, Molecular Probes; diluted 1:250 in PBS-T). Cells
were then washed three times and incubated for 15 min with the nuclear stain
TO-PRO-3 (Molecular Probes; diluted 1:1000 in ddH2O). Cells were rinsed with
ddH2O, and coverslips were applied using ProLong Gold antifade reagent
(Molecular Probes).
Imaging
Images were collected using an Olympus FluoView FV300 confocal laser
scanning microscope.
Human Cell Lines
Transfections were performed using LipoFectamine2000 (Invitrogen) accord-
ing to the manufacturer’s recommendations. The siRNA sequences for
KRAS, RAF1, andRAC1are provided in the Supplemental Experimental Proce-
dures. We expressed 1 mg pDEST53-KRASG12D, pCEP4-BxB-RAF1, pCEP4-
MEK1-ERK2, pCEP4-DN-MEK1, pEF1-RAC1V12, pEF1-RAC1N17, pEF1-
Cdc42N17, pCMV-b-cateninS552A, pCMV-b-cateninS675A, CS2-b-cateninS191A,
CS2-b-cateninS246A, and CS2-b-cateninS605A using LipoFectamine2000.
pCMV-b-cateninS552A and pCMV-b-cateninS675A were generous gifts from
Dr. Nickolai Dulin, and CS2-b-cateninS191A, CS2-b-cateninS246A, and CS2-b-
cateninS605A were generous gifts from Dr. Fanxin Long. pEF1-RAC1V12,
pEF1-RAC1N17, and pEF1-Cdc42N17 were generous gifts from Dr. Matthew
Topham. Inhibition of COX-2 and treatment with PGE2 were accomplished as
described previously (Eisinger et al., 2007). The MTT assay was performed
according to manufacturer’s recommendations (Roche, Switzerland).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, nine fig-
ures, and two tables and can be found with this article at http://www.cell.com/
supplemental/S0092-8674(09)00251-7.
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